Xtant Medical Holdings's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 76.42.
Xtant Medical Holdings's Days Inventory for the
three
months ended in Mar. 2026 was 318.11.
Xtant Medical Holdings's Days Payable for the
three
months ended in Mar. 2026 was 47.75.
Therefore, Xtant Medical Holdings's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 346.78.
Xtant Medical Holdings (AMEX:XTNT) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Xtant Medical Holdings Cash Conversion Cycle Related Terms
Xtant Medical Holdings Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Xtant Medical Holdings's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xtant Medical Holdings Cash Conversion Cycle Chart
XTNT vs MDAI, QTI, POSC: Cash Conversion Cycle Comparison
For the Medical Devices subindustry, Xtant Medical Holdings's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xtant Medical Holdings Cash Conversion Cycle vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xtant Medical Holdings's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Xtant Medical Holdings's Cash Conversion Cycle falls into.
Xtant Medical Holdings Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Xtant Medical Holdings's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xtant Medical Holdings (XTNT) has a Cash Conversion Cycle of 346.78 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Xtant Medical Holdings and its competitors.
Is Xtant Medical Holdings' Cash Conversion Cycle too high?
Xtant Medical Holdings' current Cash Conversion Cycle is 346.78. The Medical Devices & Instruments industry median Cash Conversion Cycle is 156.96. Xtant Medical Holdings' value of 346.78 is 120.9% above this industry median. Overall, Xtant Medical Holdings has a GF Score™ of 31/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Xtant Medical Holdings' Cash Conversion Cycle compare to MDAI and QTI?
Xtant Medical Holdings' Cash Conversion Cycle of 346.78 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash Conversion Cycle is 156.96. Xtant Medical Holdings' value of 346.78 is 120.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Devices & Instruments company?
The median Cash Conversion Cycle among Medical Devices & Instruments companies is 156.96, based on 818 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xtant Medical Holdings's current Cash Conversion Cycle of 346.78 is 120.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Xtant Medical Holdings and its competitors. For the Medical Devices & Instruments industry, the median Cash Conversion Cycle is 156.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xtant Medical Holdings's current Cash Conversion Cycle is 346.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xtant Medical Holdings stock overvalued right now?
Based on GuruFocus' analysis, Xtant Medical Holdings (XTNT) is currently considered Possible Value Trap. The stock's GF Value™ is $0.62, compared to a current price of $0.42 — trading 32.2% below its estimated fair value. The current Cash Conversion Cycle is 346.78 and 120.9% above the Medical Devices & Instruments industry median of 156.96. Xtant Medical Holdings' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Xtant Medical Holdings (XTNT), the current Cash Conversion Cycle is 346.78 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xtant Medical Holdings (XTNT) Overvalued in 2026?
Based on GuruFocus' analysis, Xtant Medical Holdings stock appears to be undervalued.
The current stock price of $0.42 is trading 32.2% below its estimated GF Value™ of $0.62.
GuruFocus considers Xtant Medical Holdings to be Possible Value Trap.
Key valuation signals for XTNT:
Cash Conversion Cycle: 346.78
GF Value™: $0.62 vs. price of $0.42 (32.2% below fair value)
Industry Position: 120.9% above the Medical Devices & Instruments median
No single metric tells the full story. See the XTNT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.
31GF Score
Get the complete analysis for XTNT
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTNT has been successfully added to your 
